Clinical Data AstraZeneca lung drug gets ‘surprise’ win in COPD trials BioPharma DiveThe treatment, tozorakimab, succeeded where other similar therapies failed and could help a broader group of COPD patients than Dupixent.Clinical DataRespiratoryRead full story pharminent March 27, 2026 (Last updated: March 30, 2026) BioPharma Dive The treatment, tozorakimab, succeeded where other similar therapies failed and could help a broader group of COPD patients than Dupixent. Clinical DataRespiratoryRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Novartis targets Xolair successor in buyout of startup ExcellergyNext: Otsuka picks up PTSD drug with $700M Transcend buy Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
